Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 542 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CR 2 Clear all
Completed Phase 2 Interventional

S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

NCT00093418
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
70 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Oct 30, 2026, 7:07 PM EDT
Recruiting Phase 1 Interventional

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

NCT06429449
View directory record Official record
Conditions
Leukemia, Myeloid Leukemia, Monocytic Leukemia
Interventions
Venetoclax, Azacitidine, Mitoxantrone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 30, 2026, 7:07 PM EDT
Completed Phase 2 Interventional Results available

Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT02096055
View directory record Official record
Conditions
Untreated Adult Acute Myeloid Leukemia
Interventions
Cladribine, Guadecitabine, Idarubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
70 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 30, 2026, 7:07 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy

NCT04666740
View directory record Official record
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Homologous Recombination Deficiency (HRD)
Interventions
Pembrolizumab, Olaparib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 30, 2026, 7:07 PM EDT
Recruiting Phase 2 Interventional

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT03516617
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Laboratory Biomarker Analysis, Obinutuzumab, Patient Observation, Quality-of-Life Assessment
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 7:07 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

NCT00047320
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumors, Childhood Germ Cell Tumor
Interventions
carboplatin, etoposide, ifosfamide, thiotepa, adjuvant therapy, conventional surgery, neoadjuvant therapy, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 24 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 79 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 30, 2026, 7:07 PM EDT
Recruiting Not applicable Interventional

Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

NCT02792270
View directory record Official record
Conditions
Tumor Surgery
Interventions
Caloric Restriction Diet
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 7:07 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Pedaling at a Low-Moderate Intensity During Chemotherapy Administration

NCT04258969
View directory record Official record
Conditions
Colorectal Cancer, Exercise, Aerobic, Chemotherapy, Chemotherapeutic Toxicity
Interventions
Pedaling
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 30, 2026, 7:07 PM EDT
Terminated Phase 1 Interventional

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

NCT04853329
View directory record Official record
Conditions
CD20 Positive Non Hodgkin Lymphoma
Interventions
CPO107
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 30, 2026, 7:07 PM EDT
Terminated Phase 2 Interventional Results available

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

NCT03044353
View directory record Official record
Conditions
Amyloidosis
Interventions
GSK2315698 (CPHPC), GSK2398852 (anti-SAP mAb)
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 30, 2026, 7:07 PM EDT
Terminated Phase 4 Interventional Results available

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

NCT00429169
View directory record Official record
Conditions
Depression
Interventions
Paroxetine, Bupropion
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 30, 2026, 7:07 PM EDT
Completed Phase 1 Interventional

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

NCT02181218
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
Interventions
Romidepsin, Gemcitabine, Oxaliplatin, Dexamethasone, Pegfilgrastim
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 30, 2026, 7:07 PM EDT
Terminated Phase 1 Interventional

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

NCT04196010
View directory record Official record
Conditions
Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor, Mitoxantrone
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 30, 2026, 7:07 PM EDT
Terminated Phase 1 Interventional

Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

NCT05393713
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma, Metastatic Melanoma, Recurrent Metastatic Melanoma
Interventions
Anti-PD-L1 Monoclonal Antibody IMC-001, Punch Biopsy
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 30, 2026, 7:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community Resilience Learning Collaborative and Research Network

NCT03977844
View directory record Official record
Conditions
Depression, Social Stress, Anxiety, Quality of Life, Disaster
Interventions
Technical Assistance, Community Engagement and Planning, Community Resources (CR), Community Resources + eBT
Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 30, 2026, 7:07 PM EDT
Completed Not applicable Interventional Results available

A Study to Compare the NexGen CR and CR-Flex Knee Implants

NCT00761956
View directory record Official record
Conditions
Total Knee Arthroplasty, Osteoarthritis
Interventions
NexGen CR-Flex Fixed Bearing Knee, NexGen CR Knee
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
21 Years to 80 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Milford, Delaware • Chicago, Illinois • Rockford, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 30, 2026, 7:07 PM EDT
Recruiting Not applicable Interventional

Effectiveness of Exercise After an ICD

NCT03544489
View directory record Official record
Conditions
Heart Arrest, Implantable Defibrillator User, Physical Activity
Interventions
E-ICD Intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 7:07 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

NCT05365035
View directory record Official record
Conditions
Myelodysplastic Syndromes, Myeloproliferative Chronic Myelomonocytic Leukemia
Interventions
Cladribine, Cytarabine, Venetoclax, Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 30, 2026, 7:07 PM EDT
Completed Phase 2 Interventional Results available

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

NCT02591615
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MK-3475, Carboplatin, Paclitaxel, Pemetrexed
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
La Jolla, California • Chicago, Illinois • Evanston, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 30, 2026, 7:07 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Obsessive Compulsive Disorder in Children

NCT00074815
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Serotonin reuptake inhibitors management, Cognitive behavioral therapy by a psychologist, Instructional cognitive behavioral therapy by a psychiatrist
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
7 Years to 17 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
3
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 30, 2026, 7:07 PM EDT
Recruiting Not applicable Interventional

Cereset Research Exploratory Study

NCT03777267
View directory record Official record
Conditions
Neurological Diseases or Conditions, Cardiovascular Conditions After Birth, Psychophysiologic Disorders
Interventions
Active CR
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
11 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 30, 2026, 7:07 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Lung Nodule Sensitivity of Stationary Chest Tomosynthesis in Patients With Known Lung Nodules

NCT02075320
View directory record Official record
Conditions
Signs and Symptoms
Interventions
Stationary Digital Chest Tomosynthesis
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 30, 2026, 7:07 PM EDT
Terminated Phase 2 Interventional Results available

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

NCT04778410
View directory record Official record
Conditions
Myeloid Malignancies
Interventions
Magrolimab, Azacitidine, Venetoclax, Mitoxantrone, Etoposide, Cytarabine, CC-486
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 30, 2026, 7:07 PM EDT
Recruiting Phase 1Phase 2 Interventional

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

NCT06137144
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL
Interventions
AZD3470, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 7:07 PM EDT